Laura Montelisciani

Dr. Laura Montelisciani

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Metabolites
Verified
Journal Article
Open access
PDF file
SGSimonetta Genovesi
Simonetta Genovesi
LMLaura Montelisciani
Laura Montelisciani
MGMarco Cesare Giussani
Marco Cesare Giussani
GLGiulia Lieti
Giulia Lieti
APANTONELLA ILENIA PATTI
ANTONELLA ILENIA PATTI
GPGianfranco Parati
Gianfranco Parati
Excess weight and high waist circumference (WC) are associated with increased blood pressure (BP), starting from the pediatric age. Insulin resistance is associated with elevated BP in childhood. The aim of the study was to assess the role of insulin resistance in mediating the relationship between body mass index (BMI), WC, and BP values in a pediatric population referred to a cardio-pediatric center for the presence of one or more cardiovascular risk factors. In 419 children (mean age 10.7 [standard deviation, SD 2.5] years), the following parameters were collected both in basal conditions and after 18.6 (SD 9.3) months of follow-up during which a treatment based on lifestyle and dietary modifications was given: systolic and diastolic BP (SBP and DBP), WC, plasma glucose, and insulin values. The HOMA (Homeostasis Model Assessment)-index was considered as an expression of insulin resistance. At baseline there was a significant correlation between HOMA-index and SBP z-score (β = 0.081, p = 0.003), and insulin resistance was a mediator of the relationship between BMI and SBP z-score (p = 0.015), and between waist circumference to height (WtHr) and SBP z-score (p = 0.008). The effect of BMI z-score modifications on SBP z-score changes from baseline to follow-up was totally mediated by HOMA-index changes (p = 0.008), while HOMA-index only partially mediated the effect of WtHr modifications on SBP z-score changes (p = 0.060). Our study strongly suggests that, in a pediatric population at cardiovascular risk, the HOMA-index is an important mediator of the relationship between BMI, WC and SBP.

16 December 2022 in European Journal of Haematology
Verified
Journal Article
Open access
EIElena Inzoli
Elena Inzoli
ECElena Crisa
Elena Crisa
NPNovella Pugliese
Novella Pugliese
ICIvan Civettini
Ivan Civettini
GLGiuseppe Lanzarone
Giuseppe Lanzarone
Elena Maria ElliElena Maria Elli
Elena Maria Elli
Objectives: Erythropoiesis-stimulating agents (ESA) have an established role in treating anemia in hematological malignancies. However, their role, particularly biosimilar ESA (B-ESA), in myelofibrosis (MF) is not well established.Methods: This study retrospectively collected data on 96 MF patients treated with B-ESA (alpha/zeta) for the management of anemia to assess safety, efficacy (anemia response [AR]), and survival.Results: Seventy-seven patients (80%) obtained AR. The median time to AR was 2.5 months. In multivariate analysis, significant predictive factors of AR were transfusion independency (p = .006) and ferritin levels < 200 ng/ml (p = .009) at baseline. After a median follow-up of 43.8 months from diagnosis, 38 patients (39%) died, 11 (28.9%) from leukemic evolution. Only two patients (2.5%) stopped B-ESA for toxicity. The 24-month survival was significantly affected by response to B-ESA (70.8% in AR vs. 55.3% in non-responder patients, p = .016). In multivariate analysis, age & LE; 70 years (p = .029) and Hb > 8.5 g/dl (p = .047) at baseline were significantly associated with improved survival, with a trend for longer survival in AR patients (p = .06).Conclusions: B-ESA seems to be an effective and well-tolerated option for anemia treatment in the MF setting. This strategy deserves further clinical investigation.

15 October 2024 in Monaldi Archives for Chest Disease
Verified
Journal Article
Open access
PDF file
DCDavide Cavasin
Davide Cavasin
UZUmberto Zanini
Umberto Zanini
LMLaura Montelisciani
Laura Montelisciani
MVMaria Grazia Valsecchi
Maria Grazia Valsecchi
LFLaura Fabbri
Laura Fabbri
FLFabrizio Luppi
Fabrizio Luppi
COVID-19 has a negative impact on the survival of respiratory patients, especially those with interstitial lung disease. This review aims to better understand the effect of COVID-19 on patients with idiopathic pulmonary fibrosis (IPF). A systematic search of MEDLINE, PubMed, Embase, and Scopus performed from December 2019 up to July 2024 identified relevant studies. Eligibility criteria included English language, sample size ≥10 patients, COVID-19 infection, and outcome measures. Two independent reviewers assessed studies using the Newcastle-Ottawa Scale for bias and extracted data. Meta-analysis employed a random-effects model, and the Grading of Recommendations Assessment, Development and Evaluation assessed evidence quality. Outcomes considered were hospitalization, intensive care unit admission, and mortality. Of the 1541 initially identified articles, 6 high-quality studies were included. Meta-analysis revealed a 34% mortality rate [95% confidence interval (CI): 21-48%], 36% hospitalization rate (95% CI: 10-75%), and 31% intensive care unit admission rate (95% CI: 7-71%) among IPF patients with COVID-19. The certainty of evidence was low or very low due to publication bias and heterogeneity. This study underscores the elevated risk of hospitalization and death in IPF patients with COVID-19, emphasizing the vulnerability of this population. Prompt and tailored care is crucial to mitigate the impact of COVID-19 on IPF patients, necessitating proactive measures, vaccination, and comprehensive management.

5 May 2026 in Health Science Reports
Verified
Journal Article
Open access
PDF file
SAStefano Ardenghi
Stefano Ardenghi
FZFEDERICO ZORZI
FEDERICO ZORZI
LMLaura Montelisciani
Laura Montelisciani
MBMarco Bani
Marco Bani
SRSelena Russo
Selena Russo
MSMaria Grazia Strepparava
Maria Grazia Strepparava
Background and Aims: Trust in medical researchers plays a critical role in orienting health‐related attitudes and behaviors, which profoundly influence healthcare outcomes, including research participation. This study aimed to contribute to the assessment of this construct by translating and validating the Italian version of the self‐administered questionnaire, Trust in Medical Researchers‐Short Scale (TMR‐SS). Methods: In March 2022, we invited participants from an existing longitudinal cohort to complete an online survey, including socio‐demographics, the General Trust Scale (GTS), the Vaccine Hesitancy Scale (VHS), the Edelman Trust in Pharmaceutics Barometer (ETPB), and the Italian back‐translated version of the TMR‐SS. Results: Confirmatory Factor Analyses confirmed the unidimensional structure of the original questionnaire, with good to excellent fit indexes. All the items in the original version were retained in the Italian adaptation. Both Cronbach's Alpha and McDonald's Omega indicated acceptable reliability. The Multi‐Group Confirmatory Factor Analysis indicated that the model was fully invariant across gender. There were no significant associations between the TMR‐SS and socio‐demographic variables. TMR‐SS inversely correlated with the VHS dimensions and positively correlated with the ETPB. There was no significant correlation between the TMR‐SS and the GTS. Conclusion: The Italian version of the TMR‐SS proved to be a valid, reliable, and easy‐to‐administer self‐report questionnaire of trust in medical researchers within the Italian context.